GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) General Information

Description

Medication manufactured for the treatment of migraines. The tablets are effective in reducing symptoms of migraines, such as nausea and sensitivity to light or sound.

Contact Information

Formerly Known As
Trexima
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Primary Office
  • OT
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)‘s full profile, request access.

Request a free trial

GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)‘s full profile, request access.

Request a free trial